Treating melasma effectively requires a multi-modal approach focusing on three primary pillars: rigorous photoprotection, inhibition of melanin synthesis, and acceleration of epidermal turnover. The 'gold standard' remains triple combination therapy (TCT), which typically incorporates hydroquinone, a topical corticosteroid, and a retinoid. This combination works synergistically to inhibit tyrosinase (the key enzyme in pigment production), decrease inflammation, and increase the shedding of pigmented keratinocytes [1], [2].
For those seeking alternatives or long-term maintenance, ingredients such as tranexamic acid—available topically or orally—have shown significant clinical efficacy in reducing the vascular component and pigment density associated with melasma [3]. Additionally, incorporating tyrosinase inhibitors like azelaic acid, kojic acid, or cysteamine can help block the biochemical pathways of melanogenesis without the long-term risks associated with hydroquinone [1]. Consistent use of broad-spectrum sunscreens, specifically those containing iron oxides to filter high-energy visible (HEV) light, is non-negotiable for preventing relapse [4].
Melasma is a complex, chronic disorder of hyperpigmentation characterised by symmetrical brown patches, primarily on the face. It is driven by a combination of genetic predisposition, UV radiation, and hormonal influences, particularly oestrogen and progesterone. Unlike simple post-inflammatory hyperpigmentation, melasma involves not just overactive melanocytes, but also a compromised basement membrane, increased vascularity, and an accumulation of solar elastosis [3], [5].
From a biochemical perspective, the condition involves the upregulation of specific pathways, including the Wnt/β-catenin and SCF/c-kit pathways, which lead to increased melanocyte maturation and dendricity. Effectively managing melasma requires addressing these underlying structural changes in the skin rather than just targeting superficial pigment. Understanding that melasma is a 'chronic' rather than 'curable' condition is vital for long-term management strategies [2], [4].
For those looking to support the brightening process alongside professional treatments, our C-Veil Citrine Tonic was formulated with Ascorbic Acid and Niacinamide to gently address uneven tone and promote a more radiant complexion. If you are exploring ways to encourage gentle epidermal turnover, Surface Renew incorporates a specialised AHA Fruit Complex and botanical enzymes to help minimise the appearance of surface discolouration without compromising the skin's delicate barrier.
FAQ
Why is sunscreen with iron oxides important for melasma?
While standard sunscreens filter UV rays, melasma is also triggered by high-energy visible (HEV) or blue light. Iron oxides, found in many tinted Australian sunscreens, provide a physical barrier that reflects this visible light, significantly reducing the risk of pigment darkening compared to non-tinted formulations [4], [6].
Is oral tranexamic acid safe for melasma treatment?
Low-dose oral tranexamic acid (TXA) has emerged as a highly effective systemic treatment for refractory melasma. It works by inhibiting the plasminogen/plasmin pathway, which reduces melanocyte-stimulating mediators. While generally safe, it requires a medical screening to rule out personal or family histories of thromboembolic disease [3], [5].
Can chemical peels or lasers be used to treat melasma?
Procedural treatments like chemical peels (using glycolic or salicylic acid) and low-fluence Q-switched lasers can be effective adjuncts. However, they must be used with caution as excessive heat or inflammation can trigger rebound hyperpigmentation. Preparation with topical pigment inhibitors for 2-4 weeks prior to procedures is recommended to minimise this risk [2], [7].
References:
[1] McKesey J, et al. Melasma Management: An Evidence-Based Review. American Journal of Clinical Dermatology. 2020;21(2):173-195. doi:10.1007/s40257-019-00488-w
[2] Ogbechie-Goderas OA, et al. Updates in Melasma: An Australian Perspective. Australasian Journal of Dermatology. 2021;62(3):281-289. doi:10.1111/ajd.13622
[3] Bala HR, et al. Oral Tranexamic Acid for the Treatment of Melasma: A Review. Dermatologic Surgery. 2018;44(6):814-825. doi:10.1097/DSS.0000000000001518
[4] Boukari F, et al. Prevention of Melasma Relapses with Sunscreen Combining Protection Against UV and Visible Light. Journal of the American Academy of Dermatology. 2015;72(1):189-190. doi:10.1016/j.jaad.2014.08.023
[5] Passeron T, et al. Melasma: Recent advances in pathophysiology and management. Journal of the European Academy of Dermatology and Venereology. 2019;33(2):256-262. doi:10.1111/jdv.15287
[6] Dumbuya H, et al. The role of visible light and oxidised iron in hyperpigmentation. Photodermatology, Photoimmunology & Photomedicine. 2020;36(6):433-439. doi:10.1111/phpp.12586
[7] Trivedi MK, et al. A review of laser and light therapies in melasma. International Journal of Women's Dermatology. 2017;3(1):11-20. doi:10.1016/j.ijwd.2017.01.004
Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any new skincare regimen. Content reviewed by a biomedical scientist.
